SK Bioscience announced on April 6 that it has appointed Sangho Ma, an expert in infectious disease research project management, as Vice President and Head of Research Support at the Bio Research Division.


Sangho Ma, Head of Research Support at SK Bioscience. SK Bioscience

Sangho Ma, Head of Research Support at SK Bioscience. SK Bioscience

View original image

This appointment was made to strengthen the company's R&D project management (PM) capabilities and open innovation, as well as to establish a comprehensive support system covering the full cycle from research planning and regulatory response to non-clinical and GCLP (Good Clinical Laboratory Practice) operations.


Ma is a seasoned expert who has overseen non-clinical and clinical development projects for pharmaceuticals and vaccines at institutions such as the Korea Health Industry Development Institute, GC Green Cross, and JW Pharmaceutical. He holds a Ph.D. in Pharmacy from Sungkyunkwan University and a master's and bachelor's degree in Chemistry from Hankuk University of Foreign Studies.


SK Bioscience has organized the Research Support Office into the Research Planning Team, Bio Regulatory Management Team, NCS (Non-Clinical Support) Team, and GCLP Team, establishing an integrated and organic research management process. Based on these enhanced research support functions, the company aims to secure a competitive edge in the development of major pipeline products, including a next-generation pneumococcal vaccine, a universal COVID-19 vaccine, RSV preventive antibodies, an Ebola vaccine, and a next-generation influenza vaccine.



Meanwhile, in January, SK Bioscience relocated its headquarters and research center to the Songdo Global R&PD Center, and has since launched full-scale projects related to Ebola, RSV, next-generation influenza, and universal COVID-19 vaccines in collaboration with international organizations and institutions. The 21-valent pneumococcal vaccine 'GBP410', being co-developed with Sanofi, is currently undergoing global Phase 3 clinical trials. The company plans to sequentially apply for IND (Investigational New Drug) approvals and initiate clinical trials for its universal COVID-19 vaccine, next-generation pneumococcal vaccine, and avian influenza vaccine within the year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing